Evidence map›Paper›PMID 40061040›Full record

ArticleEJC paediatric oncology2023

Adjuvant therapy for children treated by enucleation at diagnosis of retinoblastoma.

Yelena Diarra, Christina Brockmeyer, Karen Fischhuber, Isabel Hülsenbeck, Saskia Ting, Madlen Reschke, Tobias Kiefer, Anna Hannbücken, Maren Wagemanns, Leyla Jabbarli and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJC paediatric oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Yelena DiarraDepartment of Paediatric Haematology and Oncology, Paediatrics III, University Duisburg-Essen, University Hospital Essen, Germany.
Christina BrockmeyerDepartment of Paediatric Haematology and Oncology, Paediatrics III, University Duisburg-Essen, University Hospital Essen, Germany.
Karen FischhuberInstitute of Biostatistics and Clinical Research, University of Muenster, Germany.
Isabel HülsenbeckDepartment of Ophthalmology, University Duisburg-Essen, University Hospital Essen, Germany.
Saskia TingInstitute of Pathology, University Duisburg-Essen, University Hospital Essen, Germany.
Madlen ReschkeDepartment of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Tobias KieferDepartment of Ophthalmology, University Duisburg-Essen, University Hospital Essen, Germany.
Anna HannbückenDepartment of Paediatric Haematology and Oncology, Paediatrics III, University Duisburg-Essen, University Hospital Essen, Germany.
Maren WagemannsDepartment of Paediatric Haematology and Oncology, Paediatrics III, University Duisburg-Essen, University Hospital Essen, Germany.
Leyla JabbarliDepartment of Ophthalmology, University Duisburg-Essen, University Hospital Essen, Germany.
Selma SirinDepartment of Diagnostic Imaging, University Children's Hospital Zürich, Zürich, Switzerland.
Regina WielandDepartment of Paediatric Haematology and Oncology, Paediatrics III, University Duisburg-Essen, University Hospital Essen, Germany.
Gudrun FleischhackDepartment of Paediatric Haematology and Oncology, Paediatrics III, University Duisburg-Essen, University Hospital Essen, Germany.
Johannes H SchulteDepartment of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Martin EbingerDepartment of Pediatric Oncology and Hematology, University Children's Hospital, Tübingen, Germany.
Dietmar LohmannInstitute of Human Genetics, University Hospital Essen, University Duisburg Essen, Essen, Germany.
Bert MüllerDepartment of Ophthalmology, Charité, Berlin, Germany.
Daniela SüsskindDepartment of Ophthalmology, University of Tübingen, Germany.
Christoph SchwabDepartment of Ophthalmology, Medical University of Graz, Graz, Austria.
Ines BrechtDepartment of Pediatric Oncology and Hematology, University Children's Hospital, Tübingen, Germany.
Angelika EggertDepartment of Pediatric Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Stefan SchönbergerDepartment of Paediatric Haematology and Oncology, Paediatrics III, University Duisburg-Essen, University Hospital Essen, Germany.
Petra Ritter-SovinzDivision of Pediatric Hematology and Oncology, Medical University of Graz, Austria.
Nikolaos BechrakisDepartment of Ophthalmology, University Duisburg-Essen, University Hospital Essen, Germany.
Sophia GörickeDepartment of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Germany.
Beate TimmermannDepartment of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), West German Cancer Center (WTZ), Germany.
Eva BiewaldDepartment of Ophthalmology, University Duisburg-Essen, University Hospital Essen, Germany.
Petra KettelerDepartment of Paediatric Haematology and Oncology, Paediatrics III, University Duisburg-Essen, University Hospital Essen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Advanced localized retinoblastoma can be cured by enucleation, but extraocular spread of retinoblastoma cells is associated with a high mortality. Risk-stratified adjuvant treatment with chemotherapy and radiotherapy has been shown to reduce the risk for extraocular relapse in children with histopathological risk factors. Methods: Data of 184 patients with retinoblastoma and primary enucleation were collected in a prospective, multicenter, observational study between 2013 and 2020. The clinical characteristics were evaluated as risk factors and progression-free and overall survival rates were compared. Results: Seventy-one percent of 184 children with retinoblastoma treated with primary enucleation were diagnosed with low risk histopathological factors (pT1/pT2a) and received no adjuvant therapy. Children with intermediate risk (pT2b,pT3; 48 children, 26.0%) and high risk for metastasis (pT4; 5 children, 2.7%) received risk-stratified adjuvant treatment. None of the children with low risk or intermediate risk (pT1-pT3) relapsed, but two of five children with high-risk retinoblastoma (pT4) developed extraocular relapses and one deceased. The 2-year progression-free survival rate and 2-year overall survival rate was 100% for children with pT1-3 retinoblastoma. However, the 2-year progression-free survival rate and 2-year overall survival rate for children with pT4 was statistically notably reduced with 2 of 5 children developing progression and 1 death among the 5 children within 2 years after diagnosis. Conclusion: Primary enucleation alone and with additional risk-stratified adjuvant chemotherapy treatment provides high cure rates in patients with pT1-3 retinoblastoma, but children with pT4 retinoblastoma remain at high risk to develop extraocular retinoblastoma. International prospective clinical trials are required to evaluate reduction of intensity of adjuvant chemotherapy in some risk groups (pT2, pT3) and intensification for pT4 retinoblastoma.

Indexed as

ChemotherapyChildhood cancerChoroidal invasionMetastasisOptic nerve infiltrationRadiotherapyRB1 geneRetinoblastomaScleral invasionTNM

Identifiers

PMID40061040
PMCPMC11883903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.